Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. has demonstrated steady growth, with EsoGuard test volumes increasing by 2% year-over-year to 2,841 tests performed in 3Q25, exceeding prior estimates and showing positive sequential growth. The company is expected to experience significant revenue growth driven by expanding insurance coverage and increased engagement with Medicare, which represents approximately 50% of the addressable patient population. Furthermore, the positive outcome from the MolDX CAC meeting suggests a favorable coverage decision is on the horizon, enhancing Lucid's market positioning and potential upsides in its valuation.

Bears say

Lucid Diagnostics experienced a disappointing financial performance in the third quarter of 2025, missing consensus revenue expectations, which underlines concerns about market demand for its products, particularly EsoGuard. Additionally, despite maintaining stable operating expenses, the company incurred a pro forma net loss of $9.9 million, which indicates ongoing financial struggles and highlights potential liquidity risks in a challenging commercial environment. The decline in the number of EsoGuard tests processed compared to previous quarters further exacerbates the negative outlook, suggesting slower adoption and potential barriers to future revenue generation, compounded by risks associated with reimbursement and competition.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.